<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720626</url>
  </required_header>
  <id_info>
    <org_study_id>CSEG101A2001M</org_study_id>
    <nct_id>NCT03720626</nct_id>
  </id_info>
  <brief_title>MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients</brief_title>
  <official_title>Managed Access Program (MAP) to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients With History of Vaso-occlusive Crisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this Cohort Treatment Plan is to allow access to crizanlizumab (SEG101) for&#xD;
      eligible patients diagnosed with sickle cell disease (SCD) to prevent or reduce the frequency&#xD;
      of vaso-occlusive crises (VOC). The patient's Treating Physician should follow the suggested&#xD;
      treatment guidelines and comply with all local health authority regulations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Sickle Cell Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizanlizumab</intervention_name>
    <description>IV formulation with 30 min infusion, 5mg/kg dosage</description>
    <other_name>SEG101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Written patient informed consent must be obtained prior to start of treatment.&#xD;
&#xD;
          -  Male or female, 18 to 70 years of age (inclusive) on the day of informed consent&#xD;
             signature.&#xD;
&#xD;
          -  Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high&#xD;
             performance liquid chromatography (HPLC) [performed locally]. All sickle cell disease&#xD;
             genotypes are eligible (HbSS, HbSβ0, HbSC, HbSβ+, and others).&#xD;
&#xD;
          -  History of reoccurring VOC as assessed by the Treating Physician.&#xD;
&#xD;
          -  Patients receiving HU/HC, L-glutamine (Endari), erythropoietin stimulating agents or&#xD;
             other therapies as prevention therapy and continue to experience VOC while on any of&#xD;
             these treatments.&#xD;
&#xD;
          -  Patients can continue taking the preventive therapy.&#xD;
&#xD;
          -  Patient is not a candidate to be treated with alternative treatment options or has&#xD;
             discontinued alternative treatments due to unacceptable benefit risk as documented by&#xD;
             the Treating Physician.&#xD;
&#xD;
          -  Patient must meet the following laboratory values prior to treatment:&#xD;
&#xD;
          -  Absolute Neutrophil Count ≥1.0 x 109/L&#xD;
&#xD;
          -  Platelets ≥75 x 109/L&#xD;
&#xD;
          -  Hemoglobin (Hgb) ≥4.0 g/dL&#xD;
&#xD;
          -  Estimated glomerular filtration rate ≥ 45 mL/min&#xD;
&#xD;
          -  Direct (conjugated) bilirubin ≤2.0 x ULN&#xD;
&#xD;
          -  Alanine transaminase (ALT) ≤ 3.0 x ULN&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients eligible for this Treatment Plan must not meet any of the following criteria:&#xD;
&#xD;
          -  Is on a chronic transfusion program as defined by participating in a scheduled&#xD;
             (pre-planned) series of transfusions (simple or exchange). Episodic transfusions are&#xD;
             permitted.&#xD;
&#xD;
          -  Contraindication or hypersensitivity to any drug or metabolites from similar class as&#xD;
             crizanlizumab drug or to any excipients of the drug formulation.&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to other monoclonal antibodies, which in&#xD;
             the opinion of the Treating Physician may pose an increased risk of serious infusion&#xD;
             reaction.&#xD;
&#xD;
          -  Use of therapeutic anticoagulation (prophylactic doses permitted) or antiplatelet&#xD;
             therapy (other than aspirin or NSAIDs) within the 10 days prior to starting treatment&#xD;
&#xD;
          -  Patient has no acute pathologic processes.&#xD;
&#xD;
          -  Received a monoclonal antibody or immunomodulatory agent within 1 year of starting&#xD;
             treatment, or has documented immunogenicity to a prior biologic.&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Patients with bleeding disorders&#xD;
&#xD;
          -  Known history of testing positive for Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Patients with active Hepatitis B infections (HBsAg positive)&#xD;
&#xD;
             o Note: Patients with antecedent but no active Hepatitis B (i.e. anti-HBc positive,&#xD;
             HBsAg and HBV-DNA negative) are eligible&#xD;
&#xD;
          -  Significant active infection or immune deficiency (including chronic use of&#xD;
             immunosuppressive drugs)&#xD;
&#xD;
          -  Has a serious mental or physical illness, which, in the opinion of the Treating&#xD;
             Physician would compromise compliance to treatment.&#xD;
&#xD;
          -  QTcF ≥470 msec prior to treatment&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>vaso-occlusive crisis</keyword>
  <keyword>P-selectin</keyword>
  <keyword>SEG101</keyword>
  <keyword>crizanlizumab</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Anemia, Sickle Cell</keyword>
  <keyword>HbS Disease</keyword>
  <keyword>Hemoglobin SC Disease</keyword>
  <keyword>Sickle Cell Disorders</keyword>
  <keyword>Sickling Disorder Due to Hemoglobin S</keyword>
  <keyword>Adult</keyword>
  <keyword>Hb SS</keyword>
  <keyword>Hb SC</keyword>
  <keyword>Hb Sβ+-thalassemia</keyword>
  <keyword>Hb Sβ0-thalassemia</keyword>
  <keyword>Expanded Access Use</keyword>
  <keyword>Pain Crisis</keyword>
  <keyword>Compassionate Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

